The dosage of Rubraca varies depending on the patient's response and clinical condition.

Dosage of Rubraca

Rubraca is administered orally, with the standard recommended dose being 600 mg (two 300 mg tablets) twice daily. This dosage is suitable for patients who meet the criteria for maintenance treatment of BRCA mutation-positive ovarian cancer. It is important for clinicians to assess renal function, as dose adjustments may be required for patients with moderate to severe renal impairment. Specific guidelines regarding dosage adjustments for other indications or patient populations are not specified in the description.